DELFI Diagnostics is a biotechnology company that applies artificial intelligence and machine learning to whole-genome sequencing data. Its core technology analyzes DNA fragmentation patterns - a field known as fragmentomics - within blood samples to detect cancer at early stages. The company's approach falls within the domain of liquid biopsy, offering non-invasive diagnostic alternatives to traditional methods.
The company's lead product is the FirstLook Lung test, a non-invasive blood test designed for lung cancer screening. This test serves as a complement or alternative to conventional imaging techniques like low-dose CT scans. The company has secured over $400 million in funding to advance its diagnostic platform.
DELFI Diagnostics operates from locations in Palo Alto, California, and Baltimore. The organization describes itself as mission-driven, with a focus on developing solutions with the potential for global impact. It emphasizes scientific rigor, quality, and transparency as core operational principles in its work within cancer diagnostics.
